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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
belatacept improves patient/graft survival after 1 year versus calcineurin inhibitors based 
regimens. 
 
Study Design: Review of one randomized controlled trial published in 2010 and two 
randomized controlled trials published in 2011 were used for this review and selected 
based on their relevance to the clinical question. 
 
Data Sources: Studies were found using PubMed, and Medline Plus. 
 
Outcomes Measured: All three studies measured patient/graft survival after 12 months 
as either a primary or secondary outcome.  
 
Results: Vincenti et al (2010) showed belatacept to have a 97% patient/graft survival 
after 12 months, cyclosporine with 93% patient/graft survival rate.  Adverse events 
(tremors) in this study where noted at 5% for belatacept and 16% for cyclosporine.  In 
Rostaing et al (2011) RCT patient/graft survival was shown as 100% with belatacept and 
99% with cyclosporine.  Adverse events (pyrexia and pyelonephritis) where calculated to 
be 20% for belatacept and 19% for cyclosporine.  In Rostaing et al (2011) post hoc 
analysis patient graft survival rates for belatacept where 92.8% and cyclosporine 80.8%.  
Adverse events in this study where 54.6% for belatacept and 67.2% for cyclosporine.  
 
Conclusion:  The results of these three RCT are inconclusive as to the efficacy of 
belatacept over cyclosporine in regards to patient/graft survival after 12 months. 
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Introduction	  
Chronic kidney disease affects millions of people worldwide.  Lack of affordable 
healthcare treatment options leads to death for many of these patients.1 Millions of 
patients are receiving treatment either from dialysis or a kidney transplant in effort to stay 
alive.  Even though millions are receiving these live saving treatment options there are 
still many more patients going without treatment for one reason or another. 2 
According to the World Health Organization “in the year 2005, there were 
approximately 58 million deaths worldwide, with 35 million attributed to chronic 
disease.” 3 Even after receiving a life saving kidney transplant there are still obstacles that 
a patient faces to maintain the transplanted organ.  Two common causes of death or 
transplant failure in renal transplant patients include cardiovascular disease and chronic 
allograft nephropathy. 2 
 “There are currently 119,825 people waiting for lifesaving organ transplants in 
the U.S. of these, 99,261 await kidney transplants.” 4 The cost of kidney disease is 
straining the US healthcare system.  It is estimated that the cost for one year of medical 
expenses in addition to the kidney transplant itself is approximately $330,000.5 
Calculations estimate that the cost of treating patients for chronic kidney disease in the 
US will likely reach $48 billion per year. To treat just one person with dialysis in the 
United States it costs over $50,000.6 In the United States it is estimated that over $40 
billion was spent in 2009 for the treatment of patients with kidney disease.7 These costs 
are only expected to rise higher.  Kidney failure patient care accounts for 6.7% of 
Medicare’s total budget, which translates to less than 1% of the covered population.1 
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Progression into chronic kidney disease is attributed to two other health 
conditions, diabetes and high blood pressure.  Symptoms of chronic kidney disease 
include fatigue, decreased appetite, insomnia, edema and dry skin. Treatment options for 
patients with chronic kidney disease include hemodialysis, peritoneal dialysis, renal 
transplant or medical management with medications such as steroids.  
Calcineurin inhibitors are currently the standard of care in renal transplant 
patients, however these medications can cause nephrotoxicity due to their non-selective 
nature. Nephrotoxicity can lead to decreased renal function and eventual graft failure. 
Additionally, calcineurin inhibitors can have a negative effect on other comorbid 
conditions such as hypertension, diabetes and dyslipidemia.2 The introduction of 
belatacept vs. calcineurin inhibitors is an effort to improve renal function and decreased 
cardiovascular risks the two main reasons for transplant failure or death. Belatacept is a 
selective costimulation blocker, which is intended to avoid renal and non-renal toxicities 
such as those seen with the use of calcineurin inhibitors .2  
This paper evaluates three randomized controlled trials (RCT) comparing the use 
of belatacept versus calcineurin inhibitors in increasing patient/graft survival 1-year post 
transplant. 
 
Objective	  
The objective of this selective EBM review is to determine whether or not belatacept 
improves patient/graft survival 1-year post transplant versus calcineurin inhibitor 
regimens. 
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Methods	  	   This paper looks at two randomized controlled trials and one post hoc analysis 
randomized controlled trial.  The populations studied in these trials included adult renal 
transplant patients over the age of 18.  The interventions studied where belatacept and 
cyclosporine.  The outcomes measured where patient and graft survival. 	   The author performed searches using PUBMED and Medline databases using key 
words belatacept, cyclosporine and renal transplant.  All articles where searched in the 
English language. Each article was published in a peer-reviewed journal.  Articles where 
selected based on clinical relevance to the question addressed above.  Inclusion criteria 
included randomized controlled trials.  Exclusion criteria included previous Cochrane 
reviews.  All of the studies used similar statistics to evaluate outcomes, which included 
numbers needed to treat (NNT) and numbers needed to harm (NNH). 
Table	  1	  –	  Demographics	  of	  included	  studies	  
Study Type #Pts Age Inclusion 
criteria 
Exclusion Criteria W/d Interventions 
Rostaing8 
(2011) 
RCT 173 Mean 
43-45 
years 
-CNI-based 
maintenance 
immunosuppres
sion stable 
dosing one-
month prior.  
-cGFR between 
35-75 ml/min 
per 1.73m2 
-History or recent, 
recurrent, or severe 
AR in current 
allograft or history 
of graft loss due to 
AR 
-Positive T or B 
cell cross match, a 
C4d-positive biopsy 
in current allograft 
6 Belatacept 
regimen 5mg/kg 
given IV on 
days 1, 15, 29, 
43 and 57 and 
then every 28 
days 
Rostaing9 
(2011) 
Post-
hoc 
anal
ysis 
RCT 
1209 Mean 
53 
yrs. 
-Diabetic  
-CNI-based 
maintenance 
immunosuppres
sion stable 
dosing one-
month prior.  
-cGFR between 
-History or recent, 
recurrent, or severe 
AR in current 
allograft or history 
of graft loss due to 
AR 
-Positive T or B 
cell cross match, a 
n/a -Belatacept 
More Intensive 
regimen (MI) 
-Belatacept 
Less Intensive 
regimen (LI) 
-Cyclosporine 
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35-75 ml/min 
per 1.73m2 
C4d-positive biopsy 
in current allograft 
Vincenti1
0 (2010) 
RCT 686 Mean 
43 
->18 years old 
receiving a 
living donor or 
standard 
deceased donor 
kidney 
transplant 
->60 years old 
-Donors ≥50 years 
old who had at least 
two other risk 
factors(CVA, HTN, 
and serum 
creatinine >1.5 
mg/dL) 
159 Belatacept MI 
0-3 months: 10 
mg/kg days 1,5; 
weeks 
2,4,6,8,10,12 
4-6 months: 10 
mg/kg weeks 
16, 20, 24 
7-12 months: 5 
mg/kg every 4 
weeks 
Belatacept LI: 
0-1month 10 
mg/kg days 1,5; 
weeks 2,4 
2-3 months 10 
mg/kg weeks 8, 
12 
3-12 months 5 
mg/kg every 4 
weeks 	  
Outcome	  	   All studies measured patient/graft survival, which included rejection, failure, 
infection or death. 
Results	  
This review examined two randomized controlled trials and one post hoc analysis 
randomized controlled trial comparing the used of belatacept and a calcineurin inhibitor, 
such as cyclosporine, as a method of immunosuppression following renal transplantation. 
The study utilized adult patients who had received a kidney transplant with the inclusion 
criteria cited in Table 1.  The data reported in all three studies were dichotomous. 
In the Vincenti et al. RCT, 686 patients were used to compare belatacept versus 
cyclosporine and were included based on the inclusion criteria listed in Table 1.2  
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Exclusion criteria not indicated in Table 1 also included patients who had received any 
other non-renal solid organ transplants.  This study was conducted at 100 centers 
worldwide.  Patients were randomly placed into one of three different study groups.  The 
groups consisted of belatacept low intensity, belatacept high intensity and cyclosporine.  
The study was blinded to the dosing of the belatacept but open-label to the drug itself.  
This paper will focus on the low intensity  (LI) belatacept regimen versus cyclosporine.  
The belatacept (LI) dosing regimen is as follows; 0-1 month 10 mg/kg on days 1, 5; 
weeks 2, 4 then on months 2-3 10 mg/kg during weeks 8 and 12 then on months 3-12 5 
mg/kg every 4 weeks.  The cyclosporine regimen is as follows; initial daily dose of 4-10 
mg/kg then 0-1 month dose adjusted to 150-300 ng/mL then 2-12 months dose adjusted 
to 100-250 ng/mL.  There are three primary outcomes that where being measured in this 
study, (1) composite patient and graft survival, (2) composite renal impairment endpoint 
and (3) incidence of acute rejection.   The primary outcome of composite patient and 
graft survival will be the focus of this paper.  The primary outcomes were analyzed 
between the treatment groups using a confidence interval 97.3%, with analysis by intent–
to-treat (ITT).  The patients receiving belatacept showed a 97% patient/graft survival 
after 12 months and the patients receiving cyclosporine showed 93% patient/graft 
survival after 12 months, Table 2.  The numbers needed to treat indicate that for every 25 
patients treated with Belatacept one more case of graft failure after 12 months will be 
prevented compared to patients treated with cyclosporine. Adverse events such as tremors 
where noted in 16% of cyclosporine patients and 5% of belatacept patients, Table 3. The 
numbers needed to harm indicate that for every 9 patients treated with belatacept 1 fewer 
would experience an adverse side effect compared to the control group.  
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In the Rostaing et al RCT, 173 patients were used to compare belatacept versus 
cyclosporine.8 The patients were randomly allocated to either belatacept or their current 
calcineurin inhibitor regimen (cyclosporine or tacrolimus).  Belatacept regimen is as 
follows; 5 mg/kg infusion on days 1,15, 29, 43 and 57, then every 28 days thereafter.  
The cyclosporine regimen was to maintain trough serum concentration levels of 100-250 
ng/mL.  Patients included in this study must have had a renal transplant 6 months prior to 
but no longer than 36 before the enrollment process commenced.   Individuals where 
excluded if they had a history of graft loss due to acute rejection.  The data from this 
study was compiled from 34 different centers in various countries such as the Americas, 
Europe, Australia and India. The primary outcome measured in this study was the change 
in glomerular filtration rate from baseline to month 12.  Secondary outcomes included 
patient and graft survival.  It is this secondary outcome that will be evaluated in this 
paper. The data was analyzed with intent-to-treat with a confidence interval of 95%.  The 
experimental belatacept group resulted in no kidney transplant grafts being lost in the 
first 12 months following transplantation.  One patient in the control group died due to 
complications from a myocardial infarction, but the graft was still functioning at time of 
death, Table 2. The numbers needed to treat in this study indicated for every 99 patients 
treated with Belatacept one more case of patient/graft survival after 12 months will be 
prevented compared to the control.  Adverse events where experienced by both the 
experimental and control groups of this study. Serious adverse events where noted in 
24% of belatacept patients and 19% of cyclosporine patients.  The two most common 
serious adverse events noted where pyrexia and pyelonephritis, Table 3.  The numbers 
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needed to harm that where calculated show that 20 patients need to be treated for 1 
person to experience a serious adverse event.  
In the Rostaing et al. post hoc analysis RCT, 1209 patients were used to compare 
belatacept versus cyclosporine and were included in the study based on the inclusion 
criteria as mentioned in Table 1.9 This paper will examine the effects of belatacept low 
intensity versus cyclosporine. Patients where randomly selected to be placed into one of 
three different trial groups; belatacept medium-intensity (MI), belatacept low-intensity 
(LI) and cyclosporine. This is a post hoc analysis and the dosing regimen has been 
discussed above.  This paper will focus on the belatacept (LI) versus cyclosporine 
regimen.  The experimental group of low intensity belatacept showed a 92.8% 
patient/graft survival rate after 12 months and the cyclosporine group showed an 80.8% 
graft survival rate. As indicated in Table 2 for every 9 patients treated with the 
experimental belatacept one case of patient graft failure after 12 months will be 
prevented.  The total percentage of serious adverse side effects noted where 54.6% for 
belatacept and 67.2% for cyclosporine, Table 3. The calculated numbers needed to harm, 
Table 3, show that for every 8 patients treated with belatacept 1 case of a serious adverse 
event would occur.  
	  
Table	  2.	  Results	  of	  treatment	  efficacy	  Study	   CER	   EER	   RRR	   ARR	   NNT	  Rostaing	   0.99	   1	   0.01	   0.01	   99	  Vincenti	   0.93	   0.97	   0.04	   0.04	   25	  Rostaing	  (post-­‐hoc)	   0.80	   0.92	   0.14	   0.12	   9	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Table	  3.	  Results	  of	  treatment	  safety	  Study	   CER	   EER	   RRR	   ARR	   NNH	  Rostaing	   0.19	   0.24	   0.26	   0.05	   20	  Vincenti	   0.16	   0.05	   -­‐0.68	   -­‐0.11	   -­‐9	  Rostaing	  (post-­‐hoc)	   0.67	   0.54	   -­‐0.18	   -­‐0.12	   8	  
	  
Discussion	  
 Belatacept is an FDA approved immunosuppressant drug used in the prevention 
of organ rejection.10 Its use is contraindicated in patients who are Epstein-Barr virus 
(EBV) seronegative or if their status is unknown.10 Black box warnings for belatacept 
include increased risk for post-transplant lymphoproliferative disorder and its use in liver 
transplant patients is not recommended due to an increase in graft loss and death.10 This 
drug has not been studied in patients less than 18 years of age.10 A limitation of interest is 
the fact that the studies were open-label to the type of drug being used.  However, this 
open label requirement was necessary to monitor patient’s cyclosporine serum levels.  
Therefore, bias towards a particular drug cannot be ruled out.  
Conclusion	  
	   	  This review of belatacept versus calcineurin inhibitors shows inconclusive results 
regarding patient/graft survival at 12 months.  The numbers needed to treat across the 
three studies varies from 9 to 99, while the numbers needed to harm range from -9 to 20.  
Therefore, it is unreasonable to state whether belatacept does in fact improve patient graft 
survival after 12 months compared to the use of cyclosporine as an immunosuppressant 
following renal transplantation. An area for further investigation could be to investigate 
why patients treated with belatacept had an increase incidence of post-transplant 
lymphoproliferative disorder.   According to the University of Iowa Hospital an average 
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kidney transplant will last 10-12 years.11 An area of study could be to investigate if 
belatacept can increase the average length of graft survival. 
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